A novel “signal on-off-super on” sandwich-type aptamer sensor of CRISPR-Cas12a coupled voltage enrichment assay for VEGF detection

Yuan, Guolin; Xia, Xianru; Zhang, Jicai; Huang, Jikun; Xie, Fei; Li, Xiandong; Chen, Dongliang; Peng, Chunyan

doi:10.1016/j.bios.2022.114424

Cited by 32 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, VEGF is essential for the purpose of limiting, supervising and diagnosing the risk of heart disease. Yuan et al demonstrated for the first time that a new 'signal on-off-super on' combination drug sensing system featuring three signal scaling mechanisms was available for the sensitive and stable determination of VEGF in clinical serum samples [47]. In this work, signal amplification of VEGF was achieved by immobilizing the aptamer at an electrode modified with AuNPs@Ti 3 C 2 T x -MXene.…”

Section: Aptamers-mediated Diagnostics Strategiesmentioning

confidence: 98%

Integration of CRISPR/Cas with functional nucleic acids as versatile toolbox for non-nucleic acid target diagnostics: a review

Zhang

Chen

Shi

et al. 2023

Flex. Print. Electron.

View full text Add to dashboard Cite

Non-nucleic acid targets, consisting primarily of metal ions, organic small molecules and proteins. They act as important biomolecules or cell surface markers, supplying integrated and comprehensive bio-diagnostic information for the early diagnosis and treatment of diseases. Meanwhile, the analysis of non-nucleic acid targets also offers the foundation for individualized medicine and precision therapy. Therefore, a versatile platform for non-nucleic acid targets requires development. Clustered regularly interspaced short palindromic repeats-associated protein (CRISPR/Cas) systems is driving a revolution in medical diagnostics due to high base-resolution and isothermal signal amplification. Nevertheless, the majority of CRISPR/Cas settings reported currently are targeted for nucleic acids, leaving restricted usage to non-nucleic acid targets. This is owing to the lack of suitable signal recognition transduction elements for connecting CRISPR to non-nucleic acid targets. Functional nucleic acids (FNAs), comprising aptamers and nucleic acid enzymes, are of great concern to the biological and medical professions because of their specific target recognition and catalytic properties. As appropriate, functional recognition elements, FNAs can be integrated into CRISPR/Cas systems to exploit the powerful capabilities of both. This review emphasizes the technical tricks of integrating CRISPR/Cas systems and FNAs for non-nucleic acid targeting diagnostic applications. We first offer a general overview and the current state of research in diagnostics for CRISPR/Cas and FNAs, respectively, highlighting strengths and shortcomings. A categorical summary of non-nucleic acid-targeted diagnostics is provided, with a key emphasis on fundamental insights into the versatile non-nucleic acid-targeted diagnostic toolbox. We then review emerging diagnostic strategies based on CRISPR/Cas systems and FNAs that are fast, accurate and efficient in detecting non-nucleic acid targets. Finally, we identify the challenges that remain in this emerging field and look to the future of the field, expanding to the integration of nanomaterials, development of wearable devices and point-of-care testing.

show abstract

Section: Aptamers-mediated Diagnostics Strategiesmentioning

confidence: 98%

Integration of CRISPR/Cas with functional nucleic acids as versatile toolbox for non-nucleic acid target diagnostics: a review

Zhang

Chen

Shi

et al. 2023

Flex. Print. Electron.

View full text Add to dashboard Cite

show abstract

“…The indiscriminate cleavage activity of the Cas enzyme can overcome HRP’s detection limit in ELISA. For example, using an anti-T-anti sandwich biosensor and antibody-dsDNA as the acDNA for human IL-6 and VEGF, a highly accurate detection with more than 100 times powerful compared to ELISA was achieved [ 31 ]. Similarly, Li et al [ 29 ] adopted the apt1-T-apt2 sandwich strategy to improve upon this technology.…”

Section: Fluorescence-based Sensingmentioning

confidence: 99%

“…A modified approach of immuno-RCA assembly multiplies signals from long ssDNA for bacterial strain-specific aptamers and targets repetitive acDNAs. Further, a sandwich-type “apt1-T-apt2” CRISPR sensing on AuNPs@Ti 3 C 2 T x -Mxene surface and aptamer for VEGF could detect sub-picomolar range [ 31 ]. To overcome some of the limitations of these assays, an immobilization-free EC sensor with stacking interaction between DNA molecules and the reduced GO/GCE was established [ 40 ] and demonstrated for successful detection of thrombin with as low as single femtomoles.…”

Section: Electrochemical-based Sensingmentioning

confidence: 99%

Aptamer-based CRISPR-Cas powered diagnostics of diverse biomarkers and small molecule targets

et al. 2023

View full text Add to dashboard Cite

CRISPR-Cas systems have been widely used in genome editing and transcriptional regulation. Recently, CRISPR-Cas effectors are adopted for biosensor construction due to its adjustable properties, such as simplicity of design, easy operation, collateral cleavage activity, and high biocompatibility. Aptamers’ excellent sensitivity, specificity, in vitro synthesis, base-pairing, labeling, modification, and programmability has made them an attractive molecular recognition element for inclusion in CRISPR-Cas systems. Here, we review current advances in aptamer-based CRISPR-Cas sensors. We briefly discuss aptamers and the knowledge of Cas effector proteins, crRNA, reporter probes, analytes, and applications of target-specific aptamers. Next, we provide fabrication strategies, molecular binding, and detection using fluorescence, electrochemical, colorimetric, nanomaterials, Rayleigh, and Raman scattering. The application of CRISPR-Cas systems in aptamer-based sensing of a wide range of biomarkers (disease and pathogens) and toxic contaminants is growing. This review provides an update and offers novel insights into developing CRISPR-Cas-based sensors using ssDNA aptamers with high efficiency and specificity for point-of-care setting diagnostics.

show abstract

“…The linear range was up to three orders of magnitude, with a LOD of 0.2 nM, while the detection was completed in 60 min. Very recently, Yuan et al reported the CRISPR/Cas12a coupled voltage enrichment by coupling electrochemical and CRISPR systems [ 96 ]. The authors designed two aptamers, Apt VEGF-HBD -T18-MB and Apt VEGF-RBD , which can specifically recognize the HBD and RBD domains of vascular endothelial growth factor (VEGF), respectively.…”

Section: Aptamer-assisted Crispr/cas-based Protein Detectionmentioning

confidence: 99%

Section: Aptamer-assisted Crispr/cas-based Protein Detectionmentioning

confidence: 99%

Recent Advances in CRISPR/Cas-Based Biosensors for Protein Detection

et al. 2022

View full text Add to dashboard Cite

CRISPR is an acquired immune system found in prokaryotes that can accurately recognize and cleave foreign nucleic acids, and has been widely explored for gene editing and biosensing. In the past, CRISPR/Cas-based biosensors were mainly applied to detect nucleic acids in the field of biosensing, and their applications for the detection of other types of analytes were usually overlooked such as small molecules and disease-related proteins. The recent work shows that CRISPR/Cas biosensors not only provide a new tool for protein analysis, but also improve the sensitivity and specificity of protein detections. However, it lacks the latest review to summarize CRISPR/Cas-based biosensors for protein detection and elucidate their mechanisms of action, hindering the development of superior biosensors for proteins. In this review, we summarized CRISPR/Cas-based biosensors for protein detection based on their mechanism of action in three aspects: antibody-assisted CRISPR/Cas-based protein detection, aptamer-assisted CRISPR/Cas-based protein detection, and miscellaneous CRISPR/Cas-based methods for protein detection, respectively. Moreover, the prospects and challenges for CRISPR/Cas-based biosensors for protein detection are also discussed.

show abstract

A novel “signal on-off-super on” sandwich-type aptamer sensor of CRISPR-Cas12a coupled voltage enrichment assay for VEGF detection

Cited by 32 publications

References 31 publications

Integration of CRISPR/Cas with functional nucleic acids as versatile toolbox for non-nucleic acid target diagnostics: a review

Integration of CRISPR/Cas with functional nucleic acids as versatile toolbox for non-nucleic acid target diagnostics: a review

Aptamer-based CRISPR-Cas powered diagnostics of diverse biomarkers and small molecule targets

Recent Advances in CRISPR/Cas-Based Biosensors for Protein Detection

Contact Info

Product

Resources

About